{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:06:32Z","timestamp":1745035592950,"version":"3.40.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,18]]},"DOI":"10.7759\/cureus.82509","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T11:55:31Z","timestamp":1744977331000},"source":"Crossref","is-referenced-by-count":0,"title":["Multiple System Atrophy (Cerebellar Type) With Overlapping Progressive Muscular Atrophy Features and Genetic Erb-B2 Receptor Tyrosine Kinase 4 (ERBB4) Amyotrophic Lateral Sclerosis Variant: A Case Report"],"prefix":"10.7759","author":[{"given":"Enrique Lorenzo  C","family":"Panganiban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond  L","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88732","article-title":"Addressing the role of edaravone in the management of amyotrophic lateral sclerosis and gaps in care and access: expert panel recommendations","volume":"27","author":"Barrington CJ","year":"2021","unstructured":"Barrington CJ, Burruano M, Carney C, et al.. Addressing the role of edaravone in the management of amyotrophic lateral sclerosis and gaps in care and access: expert panel recommendations. Am J Manag Care. 2021, 27:S231-7. 10.37765\/ajmc.2021.88732","journal-title":"Am J Manag Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11020195","article-title":"Effects of the edaravone, a drug approved for the treatment of amyotrophic lateral sclerosis, on mitochondrial function and neuroprotection","volume":"11","author":"Cha SJ","year":"2022","unstructured":"Cha SJ, Kim K. Effects of the edaravone, a drug approved for the treatment of amyotrophic lateral sclerosis, on mitochondrial function and neuroprotection. Antioxidants (Basel). 2022, 11:195. 10.3390\/antiox11020195","journal-title":"Antioxidants (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2019.10.004","article-title":"Multiple system atrophy","volume":"149","author":"Fanciulli A","year":"2019","unstructured":"Fanciulli A, Stankovic I, Krismer F, Seppi K, Levin J, Wenning GK. Multiple system atrophy. Int Rev Neurobiol. 2019, 149:137-92. 10.1016\/bs.irn.2019.10.004","journal-title":"Int Rev Neurobiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20548","article-title":"Atypical parkinsonism of Japan: amyotrophic lateral sclerosis-parkinsonism-dementia complex of the Kii peninsula of Japan (Muro disease): an update","volume":"20","author":"Kuzuhara S","year":"2005","unstructured":"Kuzuhara S, Kokubo Y. Atypical parkinsonism of Japan: amyotrophic lateral sclerosis-parkinsonism-dementia complex of the Kii peninsula of Japan (Muro disease): an update. Mov Disord. 2005, 20:S108-13. 10.1002\/mds.20548","journal-title":"Mov Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz189","article-title":"Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study","volume":"142","author":"Miki Y","year":"2019","unstructured":"Miki Y, Foti SC, Asi YT, Tsushima E, Quinn N, Ling H, Holton JL. Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain. 2019, 142:2813-27. 10.1093\/brain\/awz189","journal-title":"Brain"},{"key":"ref6","article-title":"Coenzyme Q10 in multiple system atrophy","author":"Mitsui J","year":"2023","unstructured":"Mitsui J, Tsuji S. Coenzyme Q10 in multiple system atrophy. Trials for Cerebellar Ataxias. Contemporary Clinical Neuroscience. Soong BW, Manto M, Brice A, Pulst SM (ed): Springer, Cham, Switzerland; 2023. 679-90."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33746","article-title":"Investigating edaravone use for management of amyotrophic lateral sclerosis (ALS): a narrative review","volume":"15","author":"Neupane P","year":"2023","unstructured":"Neupane P, Thada PK, Singh P, et al.. Investigating edaravone use for management of amyotrophic lateral sclerosis (ALS): a narrative review. Cureus. 2023, 15:e33746. 10.7759\/cureus.33746","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.662474","article-title":"Neuregulins in neurodegenerative diseases","volume":"13","author":"Ou GY","year":"2021","unstructured":"Ou GY, Lin WW, Zhao WJ. Neuregulins in neurodegenerative diseases. Front Aging Neurosci. 2021, 13:662474. 10.3389\/fnagi.2021.662474","journal-title":"Front Aging Neurosci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13596","article-title":"The hot cross bun sign: a journey across etiologies","volume":"9","author":"Prasad S","year":"2022","unstructured":"Prasad S, Rossi M. The hot cross bun sign: a journey across etiologies. Mov Disord Clin Pract. 2022, 9:1018-20. 10.1002\/mdc3.13596","journal-title":"Mov Disord Clin Pract"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2020.572013","article-title":"The dual nature of Onuf's nucleus: neuroanatomical features and peculiarities, in health and disease","volume":"14","author":"Schellino R","year":"2020","unstructured":"Schellino R, Boido M, Vercelli A. The dual nature of Onuf's nucleus: neuroanatomical features and peculiarities, in health and disease. Front Neuroanat. 2020, 14:1-13.","journal-title":"Front Neuroanat"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2013.09.008","article-title":"ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19","volume":"93","author":"Takahashi Y","year":"2013","unstructured":"Takahashi Y, Fukuda Y, Yoshimura J, et al.. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet. 2013, 93:900-5. 10.1016\/j.ajhg.2013.09.008","journal-title":"Am J Hum Genet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.865264","article-title":"Analysis of ErbB4 variants in amyotrophic lateral sclerosis within a Chinese cohort","volume":"13","author":"Wang F","year":"2022","unstructured":"Wang F, Liu X, He J, Zhang N, Chen L, Tang L, Fan D. Analysis of ErbB4 variants in amyotrophic lateral sclerosis within a Chinese cohort. Front Neurol. 2022, 13:865264. 10.3389\/fneur.2022.865264","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.22082","article-title":"Multiple system atrophy: advances in diagnosis and therapy","volume":"16","author":"Watanabe H","year":"2023","unstructured":"Watanabe H, Shima S, Mizutani Y, Ueda A, Ito M. Multiple system atrophy: advances in diagnosis and therapy. J Mov Disord. 2023, 16:13-21. 10.14802\/jmd.22082","journal-title":"J Mov Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/362161-multiple-system-atrophy-cerebellar-type-with-overlapping-progressive-muscular-atrophy-features-and-genetic-erb-b2-receptor-tyrosine-kinase-4-erbb4-amyotrophic-lateral-sclerosis-variant-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T11:55:32Z","timestamp":1744977332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/362161-multiple-system-atrophy-cerebellar-type-with-overlapping-progressive-muscular-atrophy-features-and-genetic-erb-b2-receptor-tyrosine-kinase-4-erbb4-amyotrophic-lateral-sclerosis-variant-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.82509","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}